Jones Financial Companies Lllp raised its stake in Allergan PLC. (NYSE:AGN) by 43.1% during the first quarter, according to its most recent disclosure with the SEC. The firm owned 8,878 shares of the company’s stock after buying an additional 2,676 shares during the period. Jones Financial Companies Lllp’s holdings in Allergan PLC. were worth $2,121,000 as of its most recent filing with the SEC.
Several other large investors have also modified their holdings of the company. Senzar Asset Management LLC purchased a new position in Allergan PLC. during the fourth quarter valued at $33,329,000. Jarislowsky Fraser Ltd purchased a new position in Allergan PLC. during the fourth quarter valued at $209,000. Numeric Investors LLC purchased a new position in Allergan PLC. during the fourth quarter valued at $609,000. Wills Financial Group Inc. purchased a new position in Allergan PLC. during the fourth quarter valued at $487,000. Finally, Pittenger & Anderson Inc. raised its position in Allergan PLC. by 12.9% in the fourth quarter. Pittenger & Anderson Inc. now owns 7,440 shares of the company’s stock valued at $1,562,000 after buying an additional 850 shares during the last quarter. Institutional investors own 84.77% of the company’s stock.
Shares of Allergan PLC. (NYSE AGN) traded down 0.61% during trading on Tuesday, hitting $239.74. The company had a trading volume of 2,730,642 shares. The company’s 50 day moving average is $246.48 and its 200 day moving average is $237.35. The firm has a market capitalization of $80.52 billion, a P/E ratio of 7.47 and a beta of 1.16. Allergan PLC. has a 1-year low of $184.50 and a 1-year high of $256.80.
Allergan PLC. (NYSE:AGN) last issued its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.95 by $0.07. The business had revenue of $4.01 billion during the quarter, compared to analysts’ expectations of $3.95 billion. Allergan PLC. had a return on equity of 7.25% and a net margin of 79.17%. The company’s revenue for the quarter was up 8.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.35 EPS. Analysts anticipate that Allergan PLC. will post $16.21 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Friday, August 18th will be issued a $0.70 dividend. The ex-dividend date of this dividend is Wednesday, August 16th. This represents a $2.80 dividend on an annualized basis and a yield of 1.17%. Allergan PLC.’s payout ratio is 9.95%.
AGN has been the topic of a number of research reports. Royal Bank Of Canada set a $279.00 target price on shares of Allergan PLC. and gave the stock a “buy” rating in a report on Wednesday, April 12th. Mizuho decreased their price objective on shares of Allergan PLC. from $275.00 to $267.00 and set a “buy” rating on the stock in a report on Friday, June 9th. Cowen and Company set a $400.00 price objective on shares of Allergan PLC. and gave the company a “buy” rating in a report on Thursday, June 8th. UBS AG restated a “buy” rating and issued a $275.00 price target on shares of Allergan PLC. in a research note on Monday, May 15th. Finally, Citigroup Inc. upped their price target on shares of Allergan PLC. to $261.00 and gave the company a “buy” rating in a research note on Monday, April 24th. Seven equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $274.14.
In other Allergan PLC. news, Director Nesli Basgoz sold 1,889 shares of the business’s stock in a transaction that occurred on Thursday, May 18th. The stock was sold at an average price of $220.45, for a total transaction of $416,430.05. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.36% of the company’s stock.
About Allergan PLC.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with our FREE daily email newsletter.